Aripiprazole may be free from tachyphylaxis: preliminary findings

Psychiatry Clin Neurosci. 2012 Mar;66(2):160-2. doi: 10.1111/j.1440-1819.2011.02301.x. Epub 2012 Feb 2.


Loss of antipsychotic efficacy (tachyphylaxis), possibly linked to an increase in D₂ receptor number and sensitivity, is a significant impediment to treatment in chronic schizophrenia patients. Animal studies, however, suggest that aripiprazole may be free from tachyphylaxis. The aim of the present study was to investigate this hypothesis. In this preliminary study, aripiprazole-treated patients were retrospectively investigated for the presence or absence of tachyphylaxis. Clinical Global Impression-Improvement (CGI-I) scores did not significantly change and there was no significant association of CGI scores with fixed dose duration. This suggests that aripiprazole may be free from tachyphylaxis.

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Quinolones / therapeutic use*
  • Schizophrenia / drug therapy*
  • Tachyphylaxis*
  • Treatment Outcome


  • Antipsychotic Agents
  • Piperazines
  • Quinolones
  • Aripiprazole